Skip to content

NASDAQ · mid · thesis board

MDGL Madrigal Pharmaceuticals

THR-β agonist (resmetirom / Rezdiffra)

View race

Thesis

Editorial summary — not a primary filing

First MASH commercial mover (Rezdiffra); defend share as FGF21s approach.

Next gate

2026-11-01Company-guidedlabel expand

Label / real-world update

15 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~16 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~497d)100%
Days to gate (15d)3%
Show math

$900M cash ÷ $55M/mo burn ≈ 497 days. Source: curated SEC quarter figures.

Cash $900M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
AKROPh3okVKTXPh2okGILDPh2ok

Risks

  • Uptake curve
  • FGF21 competition
  • Label expansion
  • Pricing

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT03900429as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01